BioWorld® - Medical Device Daily

BioWorld Industrial Biotechnology StatReport: Immediate and Comprehensive Industry Information
GlaxoSmithKline biocatalysts development
plc
agreement
Nagase & Co. biocatalysts joint development
agreement
Novartis AG cross-linked enzyme two-year R&D
crystal brand forms of
subtilisin for use in
detergents
collaboration
U.S. Department CLEC technology for $100K research
of Defense high performance
catalysts to detoxify
nerve agents
grant
RESEARCH & DEVELOPMENT: Develop highly stable forms of enzymes used in chemical synthesis
PRODUCTS ON MARKET: ChiroCLEC-BL for performing chiral resolutions and regioselective
reactions in aqueous and organic media
ChiroCLEC-CR for performing resolutions of chiral chemicals primarily
esters, alcohols, and acids
ChiroCLEC-EC for resolving alcohols, amines, and acids
ChiroCLEC-PC for resolving alcohols, acids, and esters under a variety of
reaction conditions
ChiroKit-EH for performing resolutions of alcohols, acids, and esters by
ester hydrolysis
ChiroKit-TE for performing resolutions of alcohols and amines by acylation
reactions
PeptiCLEC-BL for synthesizing peptides and peptidomimetics
PeptiCLEC-TR for performing peptide coupling of both protected and
unprotected peptides
PeptiKit for performing quick identification of best catalyst for peptide
coupling chemistry
SynthaCLEC-PA catalyst for bulk manufacture of semi-synthetic penicillin
antibiotics
PRODUCTS IN DEVELOPMENT: Name Status
TheraCLEC (ALTU-135) in Phase II clinicals, orphan
drug status
ALTU-238 for growth deficiency in Phase II clinicals
ALTU-237 for kidney stones/primary
hyperoxaluria (oral)
in preclinicals
ALTU-236 for phenylketonuria (oral) in preclinicals
Aluline Ltd.
Harbour House, 1 Aldborough Street
Blyth NE24 2EU, UK
Phone: +44 (0) 1670 544 322; Fax: +44 (0) 1670 544 340
Web: www.aluline.co.uk
E-mail: enquiry@aluline.co.uk
KEY PERSONNEL: William G. Clark; President
Caroline Clark; Exec. VP
P. Abdo; Purchasing Manager
Ian Richardson; Scientist
EMPLOYEES: 22 employees
HISTORY: Founded and began biotech R&D in 1993
FACILITIES: 1,200 sq. ft. headquarters
6,000 sq. ft. manufacturing facility
STOCK-FINANCIAL HISTORY: Privately held
Copyright ©2006 AHC Media ® 35
7/93
11/93
5/96
1/96